# US 2025/0145635 A1 · Compound containing bis(azanylylidene) sulfonyl structure and use thereof in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145635 A1
- Document ID: US20250145635A1
- Status: Published application
- Kind: A1
- Application number: 18/721,357
- Filed: 2022-12-21
- Published: 2025-05-08
- Earliest claimed: 2021-12-21
- Assignees: Scinnohub Pharmaceutical Co., Ltd
- Applicants: Scinnohub Pharmaceutical Co., Ltd.
- Inventors: Jianzong LI; Zao WANG; Shunchun ZHAO; TAO SHAO; Ruijie ZHOU; Jing WANG; Xiao HU; Yeye WANG; Xiaodong ZHANG; Jun TANG; Yuanqing TANG
- Web page: https://patentgrep.com/patent/US20250145635A1

## CPC

- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 493/04: Ortho-condensed systems
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/426: 1,3-Thiazoles
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- C07B 59/004: {Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium}
- C07D 205/06: having one double bond between ring members or between a ring member and a non-ring member
- C07D 401/14: containing three or more hetero rings
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/14: containing three or more hetero rings
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A compound containing a bis(azanylylidene) sulfonyl structure of formula (I) as a PKR agonist and/or USP9X inhibitor, which can be used for treating related diseases mediated and regulated by PKR and USP9X, wherein the related diseases comprise, but are not limited to: sickle-cell anemia, β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia, anemia of chronic diseases, colorectal cancer, kidney cancer, pancreatic cancer, breast cancer, lung cancer, esophageal cancer, melanoma, lymphoma, glioblastoma, or multiple myeloma.

## Claims

### Claim 1

A compound of formula I, or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof:
wherein,
R1, R2 and R3 are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb, —SRb, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Rc, —C(O)Rf or —C(O)ORg, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —OR, —SR, —NO2, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Re, —C(O)R and —C(O)ORg;
or, R1 and R2, R1 and R3, or R2 and R3 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, —(C5-C8)spirocyclyl, 5-8 membered spiroheterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
R4 is —NH2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb, —SRb, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Re, —C(O)Rf, —C(O)ORg or —NRc(CRhRi)t—Ra, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —SRb, —NO2, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRS(O)2Re, —NRcS(O)Re, —C(O)Rf and —C(O)ORg;
t is 0, 1, 2 or 3;
Ra, Rb, Rc, Rd, Rc, Rf, Rg, Rh and Ri at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H or —C(O)OH, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, —C(O)OH, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
or, any two groups on adjacent atoms selected from the group consisting of Ra, Rb, Rc, Rd, Rc, Rf, Rg, Rh and Ri together with atoms to which they are attached optionally bind to form C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, (C3-C8)cycloalkyl, or 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, which is optionally substituted by one or more Ra.

### Claim at position 2

2-51. (canceled)

### Claim 52 (depends on 1)

A compound of formula I or a compound of formula II, or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof:
wherein,
R1, R2 and R3 are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb, —SRb, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Re, —C(O)Rf or —C(O)ORg, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —SRb, —NO2, —NRCRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRS(O)2Re, —NRS(O)Re, —C(O)Rf and —C(O)ORg;
or, R1 and R2, R1 and R3, or R2 and R3 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, —(C5-C8)spirocyclyl, 5-8 membered spiroheterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
R4 is —NH2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb, —SRb, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Re, —C(O)Rf, —C(O)ORg or —NRc(CRhRi)t—Ra, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —SRb, —NO2, —NRcRd, —S(O)2Re, —S(O)2NRcRd, —S(O)Re, —S(O)NRcRd, —NRcS(O)2Re, —NRcS(O)Re, —C(O)Rf and —C(O)ORg;
t is 0, 1, 2 or 3;
Ra, Rb, Rc, Rd, Rc, Rf, Rg, Rh and Ri at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H or —C(O)OH, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, —C(O)OH, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
or, any two groups on adjacent atoms selected from the group consisting of Ra, Rb, Rc, Rd, Rc, Rf, Rg, Rh and Ri together with atoms to which they are attached optionally bind to form C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, (C3-C8)cycloalkyl, or 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, which is optionally substituted by one or more Ra;
wherein
R3 and R4 are as defined in claim 1;
each Rj is independently —H, halogen, —OH, —NH2, —CN, ═O, —NO2, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H, or —C(O)OH, wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —H, ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H, —C(O)OH, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, C6-C14 aryl, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
m is independently an integer selected from the group consisting of 0-6;
v is 0 or 1;
ring B is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 53 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein the compound has formula I-1 or I-2:

### Claim 54 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein
R1 and R2 are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb or —NRcRd, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —NO2, and —NRcRd;
or, R1 and R2 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl or 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
Ra, Rb, Rc, and Rd at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of 0, N and S, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —NO2, —NH2, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 55 (depends on 54)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 54, wherein
R1 and R2 are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb or —NRcRd, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —NO2, and —NRcRd;
or, R1 and R2 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
Ra, Rb, Rc, and Rd at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —NO2, —NH2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, and 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 56 (depends on 55)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 55, wherein
R1 and R2 are independently —H, —F, —Cl, —Br, —OH, —NH2, —CN, —NO2, —(C1-C6) linear alkyl, —(C1-C6) branched alkyl, —(C3-C6)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —ORb or —NRcRd, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —Ra, —ORb, and —NRcRd;
or, R1 and R2 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
Ra, Rb, Rc, and Rd at each occurrence are independently H, —F, —Cl, —Br, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, or 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —OH, —NO2, —NH2, and —(C1-C6)alkyl.

### Claim 57 (depends on 56)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 56, wherein
R1 and R2 are independently —H, —F, —Cl, —Br, —OH, —NH2, —CN, —NO2, —(C1-C6) linear alkyl, —(C1-C6) branched alkyl, —(C3-C6)cycloalkyl, or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl or heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —Ra, —ORb, and —NRcRd;
or, R1 and R2 together with atoms to which they are attached optionally bind to form —(C3-C8)cycloalkyl or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
Ra, Rb, Rc, and Rd at each occurrence are independently H, —F, —Cl, —Br, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl or heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —OH, —NO2, —NH2, and —(C1-C6)alkyl.

### Claim 58 (depends on 57)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 57, wherein
R2 is —H, —F, —Cl or —Br;
R1 is —H, —F, —Cl, —Br, —OH, —NH2, —(CH2)qCH3, —(CH2)qOH, —CH(OH)(CH2)qCH3, —C(OH)((CH2)qCH3)2,
—(CH2)qNH2, —(CH2)qNH(CH2)qCH3, —(CH2)qN((CH2)qCH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, or —(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom;
q at each occurrence is independently 0, 1, 2, 3 or 4;
or, R1 and R2 together with atoms to which they are attached optionally bind to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, tetrahydrofuran, tetrahydropyran, morpholine, dioxane, 2,3-dihydrobenzofuran ring, or tetrahydro-2H-pyran.

### Claim 59 (depends on 54)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 54, wherein
R2 is —H, —F, —Cl or —Br;
R1 is —H, —F, —Cl, —Br, —OH, —NH2,
or, R1 and R2 together with atoms to which they are attached optionally bind to form or

### Claim 60 (depends on 56)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 56, wherein
R2 is —H, —F, —Cl or —Br;
R1 is —H, —F, —Cl, —Br, —OH, —NH2, —CH3, —CH(OH)CH3, —(CH2)qCH3, —(CH2)qOH, —CH(OH)(CH2)qCH3, —C(OH)((CH2)qCH3)2, —C(OH)((CH2)qCH3)(CH3), —C(OH)(CH3)2,
—CH2F, —CHF2, —(CH2)qCH2F, —(CH2)qCHF2, —CH2Cl, —CHCl2, —(CH2)qCH2Cl, —(CH2)qCHCl2, —(CH2)qNH2, —NHCH3, —NH(CH2)qCH3, —(CH2)qNHCH3, —(CH2)qNH(CH2)qCH3, —N(CH3)2, —N((CH2)qCH3)2, —(CH2)qN(CH3)((CH2)qCH3), —(CH2)qN(CH3)2, —(CH2)qN((CH2)qCH3)2, 3-6 membered heterocycloalkyl containing 1 N atom, or —(C1-C6)alkyl substituted by 3-6 membered heterocycloalkyl containing 1 N atom;
q at each occurrence is independently 1, 2, 3 or 4;
or, R1 and R2 together with atoms to which they are attached optionally bind to form a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, oxetane, tetrahydrofuran, tetrahydropyran, morpholine, dioxane, 2,3-dihydrobenzofuran ring, or tetrahydro-2H-pyran.

### Claim 61 (depends on 54)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 54, wherein
R2 is —H, —F, —Cl or —Br;
R1 is —H, —F, —Cl, —Br, —OH, —NH2,
or, R1 and R2 together with atoms to which they are attached optionally bind to form

### Claim 62 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein
R3 is —H, halogen, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —NO2, and —NRcRd;
Ra, Rb, Rc, and Rd at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of 0, N and S, wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —NO2, —NH2, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, and 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 63 (depends on 62)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 62, wherein
R3 is —H, halogen, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —Ra, —ORb, —NO2, and —NRcRd;
Ra, Rb, Rc, and Rd at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C8 aryl, 5-8 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —NO2, —NH2, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, and 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 64 (depends on 63)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 63, wherein
R3 is —H, —F, —Cl, —Br, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, C6-C8 aryl, or 7-14 membered bicyclic fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl, aryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —Ra and —ORb;
Ra and Rb at each occurrence are independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C3-C8)cycloalkyl, or 3-6 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, wherein each of the alkyl, cycloalkyl or heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —OH, —NO2, —NH2, and —(C1-C6)alkyl.

### Claim 65 (depends on 62)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 62, wherein
R3 is —H, —F, —Cl, —Br, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, pyridyl, phenyl, benzothiazolyl, benzomorpholinyl, or benzopyrrolidinyl, wherein the pyridyl, phenyl, benzothiazolyl, benzomorpholinyl, or benzopyrrolidinyl is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —O—(C1-C6)alkyl, —O—(C3-C6)cycloalkyl, —(C1-C6)haloalkyl, —(C3-C6)halocycloalkyl, —O—(C1-C6)haloalkyl, —O—(C3-C6)halocycloalkyl, piperazinyl, and piperazinyl substituted by any number of halogen or —(C1-C6)alkyl.

### Claim 66 (depends on 62)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 62, wherein
R3 is —H, —F, —Cl, —Br, —CH3, —CH2CH3, pyridyl,

### Claim 67 (depends on 62)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 62, wherein
R3 is —H, —F, —Cl, —Br, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, pyridyl, phenyl, naphthyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl or
wherein the pyridyl, phenyl, benzothiazolyl, benzomorpholinyl, benzopyrrolidinyl, or
is optionally substituted by one or more substituents selected from the group consisting of: —F, —Cl, —Br, —CN, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —O—(C1-C6)alkyl, —O—(C3-C6)cycloalkyl, —(C1-C6)haloalkyl, —(C3-C6)halocycloalkyl, —O—(C1-C6)haloalkyl, —O—(C3-C6)halocycloalkyl, pyrazolyl, pyrazolyl substituted by any number of halogen or —(C1-C6)alkyl, piperazinyl, piperazinyl substituted by any number of halogen or —(C1-C6)alkyl;
the ring
is 3-6 membered saturated or unsaturated N-containing heterocyclyl connected through an N atom, and in addition to the N atom, the heterocyclyl optionally contains 1-2 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 68 (depends on 62)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 62, wherein
R3 is —H, —F, —Cl, —Br, —CH3, —CH2CH3,

### Claim 69 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein the compound is a compound of formula I, I-1 or I-2:
wherein
R4 is
X is a chemical bond, —(CRhRi)t—, —NRc(CRhRi)t— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, or —C(O)OH, wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —H, ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, —C(O)OH, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
m is an integer selected from the group consisting of 0-6;
n is 0, 1 or 2;
alternatively,
R4 is
X is a chemical bond, —(CRhRi)t—, —NRc(CRhRi)t— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —O—(C3-C6)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H, or —C(O)OH, wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: —H, ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H, —C(O)OH, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
m is an integer selected from the group consisting of 0-6;
n is 0, 1 or 2;
alternatively,
R4 is
X is a chemical bond, —(CRhRi)t—, —NR(CRhRi)t— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, or —C(O)OH, wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, —C(O)OH, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
m and p are independently integers selected from the group consisting of 0-6;
n is 0, 1 or 2;
ring A is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S;
alternatively,
R4 is
X is a chemical bond, —(CRhRi)t—, —NRc(CRhRi)t— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, ═O, —NH2, —CN, —NO2, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C2-C6)alkenyl, —(C2-C6)alkynyl, —(C3-C8)cycloalkyl, —(C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S, —SH, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —S(O)2OH, —S(O)OH, —NHS(O)2OH, —NHS(O)OH, —C(O)H, or —C(O)OH, wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl or fused ring group is optionally substituted by one or more substituents selected from the group consisting of: ═O, halogen, —CN, —OH, —SH, —NO2, —NH2, —S(O)2H, —S(O)2NH2, —S(O)H, —S(O)NH2, —NHS(O)2H, —NHS(O)H, —C(O)H, —C(O)OH, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, or 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S;
m and p are independently integers selected from the group consisting of 0-6;
n is 0, 1 or 2;
ring A is (C3-C8)cycloalkyl, (C4-C8)cycloalkenyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, or 7-14 membered fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 70 (depends on 69)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 69, wherein
X is a chemical bond, —CH2—, —CH2CH2—, —NHCH2—, —NHCH2CH2— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C1-C6)alkyl or —(C1-C6)alkoxy substituted by any number of halogen, oxazolyl, thiazolyl and triazolyl;
m is an integer selected from the group consisting of 0-6;
n is 0, 1 or 2;
alternatively,
X is a chemical bond, —CH2—, —CH2CH2—, —NHCH2—, —NHCH2CH2— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —(C1-C6)alkoxy, —O—(C3-C6)cycloalkyl, —(C1-C6)alkyl substituted by any number of halogen, —(C1-C6)alkoxy substituted by any number of halogen, —(C3-C6)cycloalkyl substituted by any number of halogen, —O—(C3-C6)cycloalkyl substituted by any number of halogen, oxazolyl, thiazolyl and triazolyl;
m is an integer selected from the group consisting of 0-6;
n is 0, 1 or 2;
alternatively,
X is a chemical bond, —CH2—, —CH2CH2—, —NHCH2—, —NHCH2CH2— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C1-C6)alkyl or —(C1-C6)alkoxy substituted by any number of halogen, oxazolyl, thiazolyl or triazolyl;
m and p are independently integers selected from the group consisting of 0-6;
n is 0, 1 or 2;
the ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxane, piperazine, pyrazine, or triazine;
alternatively,
X is a chemical bond, —CH2—, —CH2CH2—, —NHCH2—, —NHCH2CH2— or —O—;
represents a single bond or double bond;
Y1 is N, C or CH;
Y2 and Y3 are each independently N, CH2 or CH, and Y2 and Y3 are not both N at the same time;
each Rj is independently —H, halogen, —OH, —NH2, —CN, ═O, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C1-C6)alkyl substituted by any number of halogen, —(C1-C6)alkoxy substituted by any number of halogen, oxazolyl, thiazolyl, or triazolyl;
m and p are independently integers selected from the group consisting of 0-6;
n is 0, 1 or 2;
the ring A is furan, thiophene, oxazole, thiazole, triazole, piperidine, pyridine, pyran, thiopyran, morpholine, 1,4-dioxane, piperazine, pyrazine, triazine, 4,5-dihydro-1H-imidazole, or 1,3-dioxolane.

### Claim 71 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein
R4 is

### Claim 72 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein
R4 is

### Claim 73 (depends on 52)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 52, wherein in the compound of formula II:
each Rj is independently —H, halogen, —OH, —NH2, —CN, ═O, —(C1-C6)alkyl, —(C1-C6)alkoxy, —(C1-C6)alkyl substituted by any number of halogen, —(C1-C6)alkoxy substituted by any number of halogen, oxazolyl, thiazolyl, or triazolyl;
the ring B is (C3-C8)cycloalkyl, 3-14 membered heterocyclyl containing 1-4 heteroatoms independently selected from the group consisting of O, N and S, C6-C14 aryl, 5-14 membered heteroaryl containing 1-4 heteroatoms independently selected from the group consisting of 0, N and S, or 7-14 membered bicyclic or tricyclic fused ring group containing 0-4 heteroatoms independently selected from the group consisting of O, N and S.

### Claim 74 (depends on 73)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 73, wherein in the compound of formula II:
the ring B is 3-7 membered oxacycloalkyl or 8-10 membered azabicyclic fused heteroaryl.

### Claim 75 (depends on 74)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 74, wherein in the compound of formula II:
the ring B is oxacycloheptane, oxacyclohexane, tetrahydrofuran, oxetane, oxacyclopropane, 1H-indole or isoindoline.

### Claim 76 (depends on 75)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 75, wherein in the compound of formula II:
the ring B is

### Claim 77 (depends on 52)

The compound of formula I or a compound of formula II, or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof according to claim 52, wherein any one or more H in the compound of formula I or II are substituted by D.

### Claim 78 (depends on 77)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 77, wherein
in the compound of formula I or II, any one or more H in the structure
are substituted by D, or any one or more H in R4 are substituted by D.

### Claim 79 (depends on 78)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 78, wherein
in the compound of formula I or II, all H in the structure
are substituted by D.

### Claim 80 (depends on 77)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 77, wherein
R1, R2 or R3 is independently and optionally substituted by D when being selected as H.

### Claim 81 (depends on 1)

The compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt, or solvate thereof according to claim 1, wherein the compound is selected from the group consisting of:

### Claim 82 (depends on 1)

A PKR agonist or USP9X inhibitor comprising the compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof according to claim 1.

### Claim 83 (depends on 1)

A method of treating a PKR or USP9X mediated disease comprising administering a subject in need thereof an effective amount of the compound, or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof according to claim 1.

### Claim 84 (depends on 83)

The method according to claim 83, wherein the disease is pyruvate kinase deficiency, hemoglobinopathy, cancer, or tumor.

### Claim 85 (depends on 83)

The method according to claim 83, wherein the disease comprises sickle cell anemia, β-thalassemia, hereditary non-spherocytic hemolytic anemia, hemolytic anemia, hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia, paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia, congenital anemia, anemia of chronic disease, colorectal cancer, renal cancer, pancreatic cancer, breast cancer, lung cancer, esophageal cancer, melanoma, lymphoma, glioblastoma, or multiple myeloma.

### Claim 86 (depends on 1, 2)

An intermediate compound represented by the following formula III:
wherein, R10 is —H or an amino-protecting group, R20 is —H, an amino-protecting group or
and R4 is as defined in claim 1;
or, R10 is —H, an amino-protecting group,
wherein R1, R2 and R3 are as defined in claim 1, m, v, Rj and ring B are as defined in claim 2, R20 is —H or an amino-protecting group.

### Claim 87 (depends on 86)

The compound according to claim 86, wherein
each amino-protecting group is independently selected from the group consisting of —Cbz, -Boc, -Fmoc, -PMB, -Bn, -Trt, -Tos, or -Alloc; and/or
any one or more H in the compound of formula III are substituted by D.

### Claim 88 (depends on 86)

The compound according to claim 86, which is selected from the group consisting of:

### Claim 89 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a stereoisomer or tautomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
